Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

MICHAEL P DEL ROSARIO

Allopathic & Osteopathic Physicians Internal Medicine Hematology & Oncology

NPI
1891164307
CMS profile
4226317
Location
LAKEWOOD, CA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2023 · Entire year

$5,077.77

202 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2023 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $4,793.84 199
Education $283.93 3

By paying entity

PY2023 · entire year · sorted by reported total

Paying entityAmountRecords
Janssen Biotech, Inc. $374.64 9
Incyte Corporation $372.30 15
Merck Sharp & Dohme LLC $329.24 14
Celgene Corporation $295.88 15
Lilly USA, LLC $283.97 10
Regeneron Healthcare Solutions, Inc. $261.02 6
PFIZER INC. $253.81 14
AstraZeneca Pharmaceuticals LP $250.94 12
Astellas Pharma US Inc $226.98 8
Novartis Pharmaceuticals Corporation $225.49 11
Pharmacyclics LLC, An AbbVie Company $201.03 5
E.R. Squibb & Sons, L.L.C. $165.39 8
Gilead Sciences, Inc. $139.86 6
Coherus Biosciences Inc. $111.90 5
BeiGene USA, Inc. $108.44 4
SANOFI-AVENTIS U.S. LLC $99.95 1
Kyowa Kirin, Inc. $92.37 4
GENZYME CORPORATION $85.62 4
Daiichi Sankyo Inc. $79.64 3
Progenics Pharmaceuticals, Inc. $72.26 3
Genentech USA, Inc. $68.84 3
Bayer Healthcare Pharmaceuticals Inc. $68.12 3
Takeda Pharmaceuticals U.S.A., Inc. $62.16 2
Sumitomo Pharma America, Inc. $59.73 2
EMD Serono, Inc. $58.25 3
Jazz Pharmaceuticals Inc. $56.83 2
AVEO Pharmaceuticals, Inc. $55.00 2
Karyopharm Therapeutics Inc. $52.69 2
Exelixis Inc. $49.09 2
ImmunoGen, Inc. $48.04 2
Blueprint Medicines Corporation $39.22 2
MorphoSys, US Inc. $35.27 2
Octapharma USA, Inc. $34.02 1
PharmaEssentia USA Corporation $33.36 1
Genmab U.S., Inc. $32.58 1
Puma Biotechnology, Inc. $29.95 1
Rigel Pharmaceuticals, Inc. $28.43 2
Eisai Inc. $27.63 1
SOBI, INC $24.50 1
Myriad Genetic Laboratories, Inc. $23.96 1
Ipsen Biopharmaceuticals, Inc $23.63 1
Alexion Pharmaceuticals, Inc. $21.32 1
Agios Pharmaceuticals, Inc. $19.88 1
AbbVie Inc. $17.43 1
Chiesi USA, Inc. $16.64 1
RECORDATI_RARE_DISEASES_INC. $15.96 1
TAIHO ONCOLOGY, INC. $15.90 1
Organon LLC $14.92 1
Stemline Therapeutics Inc. $13.69 1

Page 3 of 5; records 101–150 of 202 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

MICHAEL P DEL ROSARIO

NPI 1891164307 · CMS profile ID 4226317

Allopathic & Osteopathic Physicians / Internal Medicine / Hematology & Oncology

LAKEWOOD, CA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 3 of 5; records 101–150 of 202 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1891164307?year=2023&recipient=provider&page=3#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
MICHAEL P DEL ROSARIO, NPI 1891164307, CMS profile ID 4226317. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 5; records 101–150 of 202 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1891164307?year=2023&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
APA 7
IndustryPayments. (2026). MICHAEL P DEL ROSARIO, NPI 1891164307, CMS profile ID 4226317. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 5; records 101–150 of 202 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1891164307?year=2023&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
Bluebook
MICHAEL P DEL ROSARIO, NPI 1891164307, CMS profile ID 4226317, IndustryPayments, General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 3 of 5; records 101–150 of 202 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9. https://industrypayments.org/provider/npi-1891164307?year=2023&recipient=provider&page=3#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2023

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2023 · Physicians and non-physician practitioners · CMS publication 2026-06-30

202 matching records · $5,077.77 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 202 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 101–150 of 202.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Novartis Pharmaceuticals Corporation $34.9108/09/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 991509023 CMS
Gilead Sciences, Inc. $8.3708/08/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1026085421 CMS
Astellas Pharma US Inc $22.0908/04/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1034370401 CMS
Daiichi Sankyo Inc. $28.9408/03/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1006463637 CMS
Genentech USA, Inc. $20.0708/01/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1040470213 CMS
Incyte Corporation $1.4007/28/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1044340543 CMS
Incyte Corporation $26.8707/28/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1044340551 CMS
Merck Sharp & Dohme LLC $27.8307/26/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1048508255 CMS
AstraZeneca Pharmaceuticals LP $19.2307/25/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1012102379 CMS
BeiGene USA, Inc. $27.9907/24/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1051184985 CMS
Lilly USA, LLC $5.1707/22/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1031894517 CMS
Lilly USA, LLC $22.2007/22/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1031894519 CMS
AstraZeneca Pharmaceuticals LP $19.6907/10/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1014275881 CMS
Regeneron Healthcare Solutions, Inc. $25.7806/30/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 999147211 CMS
AbbVie Inc. $17.4306/21/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 996630761 CMS
Celgene Corporation $23.4606/15/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1016157093 CMS
Myriad Genetic Laboratories, Inc. $23.9606/14/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1059770919 CMS
Merck Sharp & Dohme LLC $16.2506/13/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1048508107 CMS
Rigel Pharmaceuticals, Inc. $12.0106/12/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1033383153 CMS
Pharmacyclics LLC, An AbbVie Company $28.8206/07/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 998284485 CMS
Janssen Biotech, Inc. $34.2706/05/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 988302981 CMS
Bayer Healthcare Pharmaceuticals Inc. $18.2506/02/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1000298761 CMS
BeiGene USA, Inc. $21.8905/31/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1051184981 CMS
Astellas Pharma US Inc $23.7305/24/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1034120469 CMS
Celgene Corporation $10.3705/23/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1016157061 CMS
Incyte Corporation $99.9905/23/2023 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1044340470 CMS
AstraZeneca Pharmaceuticals LP $23.0505/18/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1016102589 CMS
Astellas Pharma US Inc $13.3705/17/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1034108807 CMS
Lilly USA, LLC $5.4905/17/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1031805745 CMS
Lilly USA, LLC $17.7205/15/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1031820439 CMS
Lilly USA, LLC $19.8805/10/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1031916491 CMS
E.R. Squibb & Sons, L.L.C. $19.2505/08/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1016157057 CMS
Merck Sharp & Dohme LLC $32.8405/05/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1048508257 CMS
Incyte Corporation $29.4005/03/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1044340527 CMS
Merck Sharp & Dohme LLC $22.3705/02/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1048508103 CMS
Incyte Corporation $28.1004/26/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1044340447 CMS
E.R. Squibb & Sons, L.L.C. $30.6104/21/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1016157031 CMS
Astellas Pharma US Inc $25.3104/18/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1034059901 CMS
Janssen Biotech, Inc. $31.0004/17/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 988303011 CMS
Exelixis Inc. $24.6404/15/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1044540529 CMS
Merck Sharp & Dohme LLC $30.5704/13/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1048508249 CMS
Celgene Corporation $27.2704/12/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1016157027 CMS
Kyowa Kirin, Inc. $19.8304/12/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1027011839 CMS
Coherus Biosciences Inc. $21.5304/11/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1060240609 CMS
PFIZER INC. $24.4704/11/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1049340933 CMS
Astellas Pharma US Inc $23.9204/05/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1034032323 CMS
Regeneron Healthcare Solutions, Inc. $24.7204/05/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 999147205 CMS
Gilead Sciences, Inc. $31.9404/04/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1025553275 CMS
Takeda Pharmaceuticals U.S.A., Inc. $28.2803/31/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1055376561 CMS
Incyte Corporation $24.0703/30/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1044340419 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $74.65 1
PY2021 $168.96 4
PY2022 $3,938.70 155
PY2023 $5,077.77 202
PY2024 $2,362.36 96
PY2025 $3,960.17 170

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Source files
Dataset page · Bulk file · PY2019 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $54,482.74 10

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

10 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Janssen Research & Development, LLC $10,733.00 12/29/2025 Non-covered Recipient Entity
HELIOS CR INC
A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer No dispute reported 06/30/2026 1175427594
Principal investigator 1 Janssen Research & Development, LLC $135.66 12/29/2025 Non-covered Recipient Entity
HELIOS CR INC
A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer No dispute reported 06/30/2026 1175427709
Principal investigator 1 Janssen Research & Development, LLC $10,733.00 12/29/2025 Non-covered Recipient Entity
HELIOS CR INC
A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer No dispute reported 06/30/2026 1175427738
Principal investigator 1 Janssen Research & Development, LLC $19,682.00 12/22/2025 Non-covered Recipient Entity
HELIOS CR INC
A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer No dispute reported 06/30/2026 1175427503
Principal investigator 1 Janssen Research & Development, LLC $173.84 12/15/2025 Non-covered Recipient Entity
HELIOS CR INC
A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer No dispute reported 06/30/2026 1175427455
Principal investigator 1 Janssen Research & Development, LLC $186.24 12/15/2025 Non-covered Recipient Entity
HELIOS CR INC
A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer No dispute reported 06/30/2026 1175427497
Principal investigator 1 Janssen Research & Development, LLC $390.00 11/20/2025 Non-covered Recipient Entity
HELIOS CR INC
A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer No dispute reported 06/30/2026 1175427435
Principal investigator 1 Janssen Research & Development, LLC $100.00 11/17/2025 Non-covered Recipient Entity
HELIOS CR INC
A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer No dispute reported 06/30/2026 1175427764
Principal investigator 1 Janssen Research & Development, LLC $8,868.00 11/07/2025 Non-covered Recipient Entity
HELIOS CR INC
A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer No dispute reported 06/30/2026 1175427510
Principal investigator 1 Janssen Research & Development, LLC $3,481.00 10/06/2025 Non-covered Recipient Entity
HELIOS CR INC
A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer No dispute reported 06/30/2026 1175427715